Mc Carthy Asset Management, Inc. Cassava Sciences Inc Transaction History

Mc Carthy Asset Management, Inc.

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Jul 20, 2022	SELL	$17.22 - $38.47 $1,170 - $2,615	-68 Closed	0 $0
Q4 2021 Feb 07, 2022	BUY	$36.77 - $90.91 $294 - $727	8 Added 13.33%	68 $3,000
Q3 2021 Nov 12, 2021	SELL	$41.79 - $135.3 $1,044 - $3,382	-25 Reduced 29.41%	60 $4,000
Q2 2021 Aug 05, 2021	SELL	$32.15 - $89.72 $482 - $1,345	-15 Reduced 15.0%	85 $7,000
Q1 2021 May 13, 2021	BUY	$7.09 - $87.95 $709 - $8,795	100 New	100 $4,000

207

14M

2.98M

6.57M

Ticker SAVA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,097,900
Market Cap $94.2M
Description
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's...

Get notified when there are updates to the investment portfolio of Mc Carthy Asset Management, Inc., based on Form 13F filings with the SEC.

Stay updated on Mc Carthy Asset Management, Inc. with notifications on news.